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S U M M A R Y
Objectives: To review the literature on the prevalence, clinical manifestations, pathogenesis, treatment,
and implications of nodding syndrome (NS).
Methods: This is a narrative review.
Results: NS is a mysterious tropical disorder that is emerging in South Sudan, southern Tanzania, and
northern Uganda. Over the past decade, thousands of children have become affected, but the prevalence
is unknown. NS is characterized by an occasional nodding of the head, which is considered as a form of
epilepsy. After symptoms appear, the patient’s health rapidly deteriorates. Seizures, stunted growth, and
mental retardation may appear. In endemic areas, NS is increasingly becoming a public health problem
with high morbidity and mortality, and severe social, psychological, and economic implications.
However, the pathogenesis is unknown. Evidence suggests a role for Onchocerca volvulus, the parasitic
ﬁlarial worm responsible for river blindness, which is highly endemic in these areas. There is no cure for
NS, and treatment is symptomatic with common anticonvulsants to improve the quality of life.
Conclusions: NS seems to be a rapidly growing problem in several eastern African countries. Although it
is starting to receive more and more attention in the scientiﬁc literature, little is known about NS. A
better understanding of the pathogenesis may lead to prevention and treatment opportunities.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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In 1962, Louise Jilek-Aall, a Norwegian physician, described a
mysterious disorder characterized by head nodding in several
children in southern Tanzania.1 Some of these children eventually
developed tonic–clonic seizures. In 1983, head nodding was also
described among several patients in Liberia.2 For years, the
disorder remained isolated in these areas. However, around
1990, physicians began observing a similar disorder in distinct
areas in southern Sudan (currently known as South Sudan).3,4 After
this, several cases of ‘head nodding’ were also observed in western
Uganda.5 The condition was ofﬁcially reported to the World Health
Organization (WHO) by Warren Cooper, a missionary doctor, from
southern Sudan in 1997 and ﬁrst described in the scientiﬁc
literature as ‘nodding disease’ in 2003.3,4
Over the last decade, the disorder has appeared to be a rapidly
growing problem in several eastern Sub-Saharan African countries.
Increasing numbers of cases have been reported in geographically
localized areas of southern Sudan, southern Tanzania, and
northern Uganda. In 2003, an estimated 300 cases were reported
in southern Sudan,6 but currently, the disorder is affecting
thousands of children in this area.7 Northern Uganda, where the* Corresponding author. Tel.: +31 64 2993008.
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important epicenter.8 In late 2009, the Ministry of Health of Uganda
reported that more than 2000 children were affected in northern
Uganda.7 In 2011, the disorder started to receive more and more
attention in journals and the scientiﬁc literature. Several reports
stated that large areas of northern Uganda were experiencing an
outbreak of the condition, with more than 1000 cases being
diagnosed between August and mid-December of that year.9 Further
outbreaks were reported in early 2012, with the disease now
spreading between districts in northern Uganda, leaving at least 170
patients dead and 3000 to 5000 others nodding continuously in
these areas.9–11 However, the exact prevalence and geographic
distribution of the disease in the affected countries is unknown.12 In
August 2012, at the ﬁrst International Scientiﬁc Meeting on Nodding
Syndrome, a consensus was reached to refer to the combination of
signs and symptoms as ‘nodding syndrome’.13
2. Clinical features and classiﬁcation
Nodding syndrome mainly affects children and adolescents.
The WHO reported that 54% of patients are male.8 Although it is
uncertain whether there exists one deﬁned clinical condition that
can be applied in all reported areas, all current news reports and
scientiﬁc publications more or less agree on the clinical course. The
ﬁrst stage of the disorder is characterized by an occasional,ses. Published by Elsevier Ltd. All rights reserved.
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the nodding differs among patients. In a study group of 62 patients,
more than half of them had daily episodes of head nodding.15 It is
suggested that the nodding is caused by a brief loss of neck muscle
tone that may be due to abnormal brain activity.7,14 Several
publications have reported that the nodding is provoked by eating,
and sometimes cold weather.5,16 However, the signiﬁcance of
these signs is unclear.14 Cases have been described where the
nodding is associated with staring spells or a short loss of muscle
tone of the upper extremities, and loss of consciousness may
occur.14 Before the nodding ﬁrst appears, most children are
considered normal.3 However, once symptoms manifest, the
patient’s health seems to deteriorate rapidly. First the nodding
becomes more frequent and longer-lasting. Later on, tonic–clonic
or psychomotor seizure episodes may develop, often leading to
collapse and injuries.16 Documented natural history studies are
lacking and little is known about the short- and long-term
outcomes,17 but over time, many children become severely weak
and stunted growth sets in.14 In addition, many decline cognitively,
which eventually may lead to mental retardation.3 In the same
study, over 40% of the 62 patients seemed to have cognitive
impairment, with half of them affected severely.15 Children lose
their attention span and their ability to interact normally.9
Furthermore, many suffer from malnutrition because they are
unable to feed themselves, partly because of the cognitive
impairment and partly because the seizures inhibit eating.7
Eventually, some patients die, often as a result of uncontrolled
seizures that may lead to traumata, drowning, or burning.3,7,9 No
child is known to have recovered from the syndrome,17 and it is
unknown whether it is communicable.9 However, the WHO
reported recently that investigations have revealed the disorder
not to be transmissible from person to person.8
Although nodding syndrome causes high morbidity and
mortality in endemic areas, the disorder is still poorly understood
and information on the syndrome is scarce. There is a wide variety
of manifestations between patients and, therefore, it is sometimes
uncertain whether people are describing the same phenome-
non.14,18 For example, it was reported that some patients initially
presented with generalized seizures instead of nodding.16 Cur-
rently, there is one clinical classiﬁcation available, subdividing the
symptoms into ‘head nodding only’ or ‘head nodding plus’, the
latter consisting of additional partial or generalized non-head
nodding epileptic seizures.14
3. Pathophysiology
The initial nodding that characterizes the syndrome is generally
considered as a form of epilepsy. This is not unexpected since head
nodding as a symptom has been associated with various epilepsy
syndromes.14 In 2002, electroencephalographs (EEGs) on 31
patients with nodding syndrome performed by a neurologist
recruited by the WHO in southern Sudan were all abnormal and
showed speciﬁc progressive epileptic encephalopathy.3,16 EEGs
between nodding episodes on 10 patients in southern Tanzania
showed an abnormal background in six of them, of whom two had
interictal epileptic activity.14 However, the authors were unable to
determine whether the seizures were focal or generalized in
nature. The assumption that nodding syndrome may be a seizure
disorder is strengthened by the fact that many patients who start
treatment with anticonvulsants have a signiﬁcant reduction in
seizure frequency.15,16
The cause of nodding syndrome as observed in South Sudan,
Tanzania, and Uganda is unclear. In the past decade, the WHO and
the US Centers for Disease Control and Prevention (CDC) have sent
several teams of experts to endemic areas to investigate the
disorder. Many possible causes have been explored by these teams,but so far they have had little success in elucidating the
pathogenesis. It was hypothesized that the disorder may be
caused by toxic residues of the biological and chemical weapons
left over from the civil war in southern Sudan. Or that it is linked to
eating the donated seeds coated with toxic chemicals that were
meant for planting,16 or to eating monkey meat.6 However, after
investigation, the WHO teams ruled out involvement of an
environmental pollutant, chemical agent, or food toxins.3 Parasi-
tological examinations established that the disorder is not caused
by infection with Trypanosoma brucei gambiense, Wuchereria
bancrofti, or Loa loa.3 In addition, CDC teams have so far not been
able to link any changes in dietary or cultural practices to the
syndrome.7 However, there might be a connection between
nodding syndrome and infection with Onchocerca volvulus. This
parasitic ﬁlarial nematode is transmitted by the black ﬂy (Simulium
species) and is responsible for river blindness, or onchocerciasis
(see Appendix 119–21). Interestingly, nearly all patients affected
with nodding syndrome are thought to live near permanent fast-
moving streams, the breeding habitat of the black ﬂy.9 In addition,
in the latter half of 2009, an upsurge of onchocerciasis infection
rates was recorded in parts of northern Uganda,22 the same parts as
where the sudden increase in nodding syndrome cases was
described during that period. Furthermore, it was observed that
93% of surveyed patients in southern Sudan were infected with O.
volvulus, compared to 63% among children without the disor-
der.6,14 However, although these data have been reported in
several reports, any further information on this study, for example
the number of patients involved, is lacking. Nevertheless, more
recent preliminary results of an investigation supported by the
WHO in southern Sudan show that 75% of the 52 patients with
nodding syndrome had a positive skin snip for O. volvulus,
compared to 47% among 38 healthy children.23 In a case–control
study performed in 2011, CDC investigators found that in one
South Sudanese community, 88% of 25 patients had positive skin
samples for the parasitic infection, compared to 44% of 25 healthy
controls.17 However, they failed to ﬁnd any difference in a second
village, with around half of the 13 patients and half of the 13
controls being infected. Results from CDC investigators in Uganda
have not been published, but it has been reported that these also
found a positive association between the worm and the
syndrome.23
These observations appear meaningful, since O. volvulus has
been associated with epilepsy before. For example, in 1992, an
unusually high number of patients with epilepsy were observed in
a rural area of western Uganda, where infection with O. volvulus is
hyperendemic.24 In addition, onchocerciasis has been associated
with the ‘Nakalanga syndrome’, which has many similarities with
nodding syndrome. This syndrome consists of epilepsy, stunted
growth, and mental retardation and has been reported from
Uganda25 and Burundi.26 In 2004, a meta-analysis of all available
epidemiological studies on the relationship between O. volvulus
and epilepsy was only able to demonstrate a nearly signiﬁcant
association.27 However, a more recent meta-analysis of epidemio-
logical studies found that for every 10% increase in the prevalence
of onchocerciasis, epilepsy rates go up by 0.4%.28
Several mechanisms have been proposed to explain the
relationship between epilepsy and onchocerciasis.29 O. volvulus
may be present in the central nervous system. Microﬁlariae have in
fact been demonstrated in the cerebrospinal ﬂuid (CSF) of
onchocerciasis patients.30 Another possibility involves immuno-
logical mechanisms. Modulators and cytokines involved in the
immunological response to the parasite may induce changes in
cerebral activity. Finally, there might be a triggering role of
insomnia due to itching. Several studies have shown a marked
activation of epileptiform abnormalities and triggering of seizures
following sleep deprivation.31
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southern Tanzania and found that 84% of the 51 children affected
with nodding syndrome carried the parasite.14 However, invasion
into the central nervous system could not be demonstrated since
only three of 48 patients had elevated levels of anti-worm immune
cells in their CSF samples. Nevertheless, it is unknown whether
these patients had used antiﬁlarial medication. Perhaps micro-
ﬁlariae were present in the CSF before treatment.32 An autoim-
mune mechanism was not investigated and could therefore not be
excluded in this study.
Potentially contradicting the possibility of the involvement of O.
volvulus in the pathogenesis of nodding syndrome is that people
living in other areas where onchocerciasis is endemic are not
affected by nodding syndrome.7 However, there are also geo-
graphical differences in the severity of other symptoms among
onchocerciasis patients, for example, ocular lesions. It has been
proposed that this might be explained by the fact that the
microﬁlariae of some O. volvulus strains are located more deeply in
the dermis than those of other strains.29 These ‘strain-dependent’
manifestations might also exist for nodding syndrome. Neverthe-
less, onchocerciasis has been prevalent in many African countries
for a very long time and, therefore, its involvement in the current
outbreak of nodding syndrome does not explain why there have
not been any outbreaks before.
Besides this parasite hypothesis, there are other possible
pathogenic mechanisms. An interesting ﬁnding is that magnetic
resonance imaging (MRI) in 12 cases showed hippocampus
pathologies in ﬁve patients and gliotic changes in ﬁve patients.14
Furthermore, familial clustering may be present, since 84% of 62
patients had at least one relative with epilepsy.14 The WHO
reported that most of the affected children suffer a deﬁciency of
vitamin B6 (pyridoxine) and other micronutrients such as vitamin
A, selenium, and zinc.33 This is currently also being investigated by
a CDC team.7,17 Some epidemiologists have suggested that climate
change may have played a part in the emergence of the syndrome,
especially if it could be deﬁnitively linked to O. volvulus.9
4. Therapy and impact
As the cause of nodding syndrome has not yet been identiﬁed,
there is no known cure. Treatment with common anticonvulsants
seems to control the symptoms in some patients. According to
health workers, patients who start treatment early and on a regular
basis have seizures less frequently and, therefore, fewer complica-
tions.16 A study has shown that treatment led to, on average, a 50%
reduction in seizure frequency.15 The administration of anti-
epileptic drugs to patients whose seizures were responsive to such
medication was recommended by a WHO team.23 However, even
without deﬁnitive evidence of the cause of the syndrome, the CDC
intends to perform interventional drug trials assessing the
effectiveness of standard anticonvulsants as well as high doses
of vitamin B6.18
Nodding syndrome is devastating to patients and communities.
As it progresses, many patients become malnourished and
completely dependent on their caregivers.9 Access to education
and standard of performance in school is low among those
affected.15 In addition, some are isolated because of the fear of
contagion.7 Several studies have shown that, in rural tropical areas,
epilepsy in general has enormous demographic and sociocultural
consequences, such as stigmatization, shorter school attendance,
decreased marriage and fecundity rates, and high mortality.34–36
Currently, many local health workers are unfamiliar with NS and
do not know how to treat patients.16 In addition, antiepileptic
drugs are often unavailable in the affected areas.16 This is a
particular worry in South Sudan, which achieved political
independence only recently and may therefore have a limitedcapacity to deal with this emerging medical threat.7 Assistance
from the international community may be necessary.
5. Conclusions and recommendations
Nodding syndrome is an unusual tropical disorder that seems to
be rapidly spreading among geographically localized areas in South
Sudan, southern Tanzania, and northern Uganda. The syndrome
appears consistent with epilepsy but with a stereotypic presenta-
tion, and there might be an association with the ﬁlarial nematode
Onchocerca volvulus. In the endemic areas, nodding syndrome is
increasingly becoming a considerable public health problem with
high morbidity and mortality, and possibly severe social, psycho-
logical, and economic implications. However, currently little is
known about its prevalence, pathogenesis, and treatment. Further
research is necessary. To date, besides several investigations carried
out by international teams provided by the World Health
Organization (WHO) and the US Centers for Disease Control and
Prevention (CDC), only one prospective study among patients has
been published.14 A better understanding of the pathogenesis may
lead to prevention and treatment opportunities. Researchers should
work closely with local ministries of health, the WHO, and the CDC in
addressing this syndrome. Cohorts should be longitudinally
compared in terms of clinical presentation and possible etiological
factors between different countries. An effective control and
surveillance program is a necessity and should be implemented
to monitor the prevalence of the syndrome, its clinical manifesta-
tions, and its geographic distribution. Geographic information
systems (GIS) could be used to monitor the emergence of the
syndrome, both spatially and in time. This could aid decision-
making and contribute to the proper allocation of resources. So far,
no (published) post-mortem studies have been performed. Such
studies might be beneﬁcial in obtaining a better insight into the
pathogenesis. Randomized controlled trials should be performed to
assess the effectiveness of proposed treatments. Because of the
assumed relationship with the black ﬂy-borne parasite O. volvulus,
mass treatment with ivermectin, a broad-spectrum antiparasitic
agent, should be reinforced in endemic areas. Furthermore, local
health workers should be trained in the identiﬁcation of the
syndrome and how to support patients psychologically and socially.
Ideally, anticonvulsant drugs should become easily accessible to
improve the quality of life and life-expectancy of patients. However,
in reality this may be hard to achieve since the epilepsy treatment
gap, the number of people with active epilepsy who are not being
appropriately treated, is gigantic in most developing countries. In
2010, a systematic review of population-based studies of epilepsy
prevalence demonstrated that this treatment gap was over 75% in
low-income countries, compared to gaps of less than 10% in many
high-income countries.37 As for Uganda and Tanzania, published
reports have demonstrated treatment gaps close to 100%.38–40
Therefore, interventions to ﬁght nodding syndrome containing
elements of epilepsy treatment are likely to have a limited impact.
Even worse, it might damage the overall efﬁciency of a program if the
respective resources are deducted from other actions with better
prospects.
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Appendix 1
Onchocerciasis
Onchocerciasis, or river blindness, is caused by the parasitic
ﬁlarial nematode Onchocerca volvulus. The disease mainly
affects people living near fast-ﬂowing rivers and is a major
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infections have occurred in Sub-Saharan Africa, but cases have
also been reported in Yemen and areas of Central and South
America.19 Overall, 120 million people live in areas of risk and
37 million people are affected worldwide, with more than 99%
of cases occurring in Sub-Saharan Africa.20 About 500 000
patients have become blind due to the disease.
Onchocerciasis is a tropical communicable disease transmitted
by black ﬂies (Simulium species) that breed in rapidly ﬂowing
fresh water. Humans are the only deﬁnitive host for O. volvulus.
The transmission cycle begins with the bite of a black ﬂy that is
infected with larvae. The larvae enter the body and mature into
adult parasites (macroﬁlariae) in 6–12 months, which inhabit
the subcutaneous tissues, sometimes coiled within ﬁbrous
nodules. Here, the adult female worm starts to produce
microﬁlariae which migrate through the skin and often into
the eyes. Once a black ﬂy bites an infected person, the cycle
starts again.
The epidemiological patterns of infection differ between
savanna and forest areas. In savanna regions, ocular onchocer-
ciasis is common, while in forest regions, a skin disease
predominates. The different clinical manifestations are thought
to be due to the existence of different strains of O. volvulus.
Serology, antigen testing, and PCR, the diagnostic tools for
infection, are generally not available in the low-resource setting
where the standard skin-snipping procedures are necessary. For
treatment, a single oral dose of ivermectin can be administered
to impair the release of microﬁlariae from worms.21 Treatments
should be repeated every 3–6 months until the patient is
asymptomatic.
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